NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
(Total Views: 162)
Posted On: 02/21/2023 3:33:43 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Findings from Hypertension Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is reporting additional findings from its human clinical study HYPER-H21-4; the study is designed to demonstrate a potentially novel mechanism of action of LEXX’s patented DehydraTECH-processed cannabidiol (“CBD”) capsule formulation in the treatment of blood pressure (“BP”). According to the announcement, Lexaria believes that those findings, which were published in the peer-reviewed “Biomedicine and Pharmacotherapy” journal, could support DehydraTECH-CBD qualification within existing Food and Drug Administration (“FDA”) guidelines. Previous results of the study indicated that primary efficacy and safety objectives were successfully achieved, including hypertensive patients seeing resting blood pressure significantly reduced and sustained over the full five weeks of dosing; results also showed that no serious adverse events have been reported during the study.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is reporting additional findings from its human clinical study HYPER-H21-4; the study is designed to demonstrate a potentially novel mechanism of action of LEXX’s patented DehydraTECH-processed cannabidiol (“CBD”) capsule formulation in the treatment of blood pressure (“BP”). According to the announcement, Lexaria believes that those findings, which were published in the peer-reviewed “Biomedicine and Pharmacotherapy” journal, could support DehydraTECH-CBD qualification within existing Food and Drug Administration (“FDA”) guidelines. Previous results of the study indicated that primary efficacy and safety objectives were successfully achieved, including hypertensive patients seeing resting blood pressure significantly reduced and sustained over the full five weeks of dosing; results also showed that no serious adverse events have been reported during the study.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼